David William Will,George Reid,Iryna Charapitsa,Joe David Lewis
申请号：
US16621580
公开号：
US20200223837A1
申请日:
2018.06.14
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to a pharmaceutical composition comprising a compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof； to the compound of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, and to certain novel compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof. Formula (I) wherein X1 is CR1 or N； X2 is CR2 or N； X3 is CR3 or N； X4 is CR4 or N； with the proviso that at most two of X1, X2, X3 and X4 are N； L1, L2 are a bond or a bivalent radical such as C1-C6-alkylene or C3-C8-cycloalkylene； A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring which may carry one or more substituents R9； or L2-A forms a group C1-C6-alkylene-OR13, C1-C6-alkylene-SR14 or C1-C6-alkylene-NR15R16； and R1, R2, R3, R4, R5, R6, R9, R13, R14, R15 and R16 are as defined in the claims and the description.
